Etanercept biosimilar (Suzhou Genemen Biotech)

依那西普生物类似药（苏州金盟生物）

Report date: 2022/07/20 13:32:46

Base Information

Drug NameEtanercept biosimilar (Suzhou Genemen Biotech)

Drug Alias Name依那西普生物仿制药（苏州金盟生物）BF-02GM-02

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionTumor necrosis factor α inhibitorsTumor necrosis factor β inhibitors

TargetsTumor necrosis factor αTumor necrosis factor β

Therapy Area/IndicationsSpondylitis, Ankylosing

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsSpondylitis, Ankylosing

Inactive IndicationsN/A

ATC CodeL04AB01